

# The prevalence, age distribution and comorbidity of personality disorders in Australian women

*Australian & New Zealand Journal of Psychiatry*  
2017, Vol. 51(2) 141–150  
DOI: 10.1177/0004867416649032

© The Royal Australian and  
New Zealand College of Psychiatrists 2016  
Reprints and permissions:  
sagepub.co.uk/journalsPermissions.nav  
journals.sagepub.com/home/anp



Editor's Choice

Shae E Quirk<sup>1</sup>, Michael Berk<sup>1,2,3,4</sup>, Julie A Pasco<sup>1,5</sup>,  
Sharon L Brennan-Olsen<sup>1,6,7</sup>, Andrew M Chanen<sup>3</sup>,  
Heli Koivumaa-Honkanen<sup>8,9</sup>, Lisa M Burke<sup>1,10</sup>, Henry J Jackson<sup>11</sup>,  
Carol Hulbert<sup>11</sup>, Craig A Olsson<sup>11,12</sup>, Paul Moran<sup>13</sup>, Amanda L  
Stuart<sup>1</sup> and Lana J Williams<sup>1</sup>

## Abstract

**Objective:** We aimed to describe the prevalence and age distribution of personality disorders and their comorbidity with other psychiatric disorders in an age-stratified sample of Australian women aged  $\geq 25$  years.

**Methods:** Individual personality disorders (paranoid, schizoid, schizotypal, histrionic, narcissistic, borderline, antisocial, avoidant, dependent, obsessive-compulsive), lifetime mood, anxiety, eating and substance misuse disorders were diagnosed utilising validated semi-structured clinical interviews (Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition and Structured Clinical Interview for DSM-IV Axis II Personality Disorders). The prevalence of personality disorders and Clusters were determined from the study population ( $n = 768$ ), and standardised to the Australian population using the 2011 Australian Bureau of Statistics census data. Prevalence by age and the association with mood, anxiety, eating and substance misuse disorders was also examined.

**Results:** The overall prevalence of personality disorders in women was 21.8% (95% confidence interval [CI]: 18.7, 24.9). Cluster C personality disorders (17.5%, 95% CI: 16.0, 18.9) were more common than Cluster A (5.3%, 95% CI: 3.5, 7.0) and Cluster B personality disorders (3.2%, 95% CI: 1.8, 4.6). Of the individual personality disorders, obsessive-compulsive (10.3%, 95% CI: 8.0, 12.6), avoidant (9.3%, 95% CI: 7.1, 11.5), paranoid (3.9%, 95% CI: 3.1, 4.7) and borderline (2.7%, 95% CI: 1.4, 4.0) were among the most prevalent. The prevalence of other personality disorders was low ( $\leq 1.7\%$ ). Being younger (25–34 years) was predictive of having any personality disorder (odds ratio: 2.36, 95% CI: 1.18, 4.74), as was being middle-aged (odds ratio: 2.41, 95% CI: 1.23, 4.72). Among the strongest predictors of having any personality disorder was having a lifetime history of psychiatric disorders (odds ratio: 4.29, 95% CI: 2.90, 6.33). Mood and anxiety disorders were the most common comorbid lifetime psychiatric disorders.

**Conclusions:** Approximately one in five women was identified with a personality disorder, emphasising that personality disorders are relatively common in the population. A more thorough understanding of the distribution of personality disorders and psychiatric comorbidity in the general population is crucial to assist allocation of health care resources to individuals living with these disorders.

## Keywords

Personality disorder; prevalence, epidemiology, comorbidity, psychiatry

<sup>1</sup>Deakin University, Geelong, VIC, Australia

<sup>2</sup>Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia

<sup>3</sup>Orygen, The National Centre of Excellence in Youth Mental Health and Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia

<sup>4</sup>The Florey Institute for Neuroscience and Mental Health, Heidelberg, VIC, Australia

<sup>5</sup>Melbourne Medical School-Western Campus, The University of Melbourne, St Albans, VIC, Australia

<sup>6</sup>Institute of Health & Ageing, Australian Catholic University, Melbourne, VIC, Australia

<sup>7</sup>Australian Institute of Musculoskeletal Sciences, The University of Melbourne, St Albans, VIC, Australia

<sup>8</sup>Institute of Clinical Medicine, Psychiatry, University of Eastern Finland, Kuopio, Finland

<sup>9</sup>Departments of Psychiatry: Kuopio University Hospital, Kuopio, Finland; South-Savonia Hospital District, Mikkeli, Finland; North Karelia Central Hospital, Joensuu, Finland; SOSTERI, Savonlinna, Finland; SOTE, Iisalmi, Finland; Lapland Hospital District, Rovaniemi, Finland

<sup>10</sup>School of Psychological Sciences, Monash University, VIC, Australia

<sup>11</sup>Melbourne School of Psychological Sciences, The University of Melbourne, Parkville, VIC, Australia

<sup>12</sup>Centre for Social and Early Emotional Development, School of Psychology, Deakin University, Geelong, VIC, Australia; Centre for Adolescent Health, Murdoch Childrens Research Institute, Parkville, VIC, Australia; Department of Paediatrics, Royal Children's Hospital, The University of Melbourne, Parkville, VIC, Australia

<sup>13</sup>Centre for Academic Mental Health, School of Social and Community Medicine, University of Bristol, Bristol, UK

#### Corresponding author:

Shae E Quirk, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Level 3 Health Education Research Building, PO BOX 281, Geelong, VIC, 3220, Australia.

Email: shae.quirk@barwonhealth.org.au

## Introduction

Currently, little is known regarding the prevalence, distribution and associated characteristics of personality disorder (PD) and their comorbidity with other psychiatric disorders in the general Australian population. Clinically-based evidence indicates that PDs are highly prevalent (45.5%) among psychiatric patients (Zimmerman et al., 2005) and are a consistent driver of impairments in social and occupational functioning (Gunderson et al., 2011; Zanarini et al., 2012), and a key risk factor for suicide attempts (Ansell et al., 2015; Zanarini et al., 2008). Despite the high levels of psychiatric comorbidity and associated functional impairment reported among those with PD in clinically-based studies, these comorbidities have remained largely unmeasured in the general Australian population.

European population-based studies have shown the prevalence of PD to range between 4.4% (England, Scotland and Wales) (Coid et al., 2006) and 13.4% (Norway) (Torgersen et al., 2001). The World Health Organization (WHO) Mental Health Surveys from Western European countries suggest that the pooled prevalence for any probable PD cases is approximately 6.1% (Huang et al., 2009). In the United States, the prevalence of PD has been reported to range between 9.0% and 21.5%, being somewhat higher than other countries (Grant et al., 2004, 2008; Lenzenweger et al., 2007; Pulay et al., 2009; Stinson et al., 2008; Trull et al., 2010). Despite methodological heterogeneity, these population-based studies demonstrate that not only are PDs common but they are also associated with overall disability (Grant et al., 2004; Jackson and Burgess, 2002; Trull et al., 2010), disruptions to employment, reduced income, poor social functioning (Coid et al., 2009; Lenzenweger et al., 2007; Sareen et al., 2011; Trull et al., 2010; Yang et al., 2010) and premature mortality (Fok et al., 2012).

It is also well known that sex disparities exist in mental health, namely, depression and anxiety, with approximately one in three Australian women being affected in their lifetime (Williams et al., 2010). There is a suggestion that some individual PDs might be particularly prevalent among women, for example, obsessive-compulsive and avoidant PDs (Grant et al., 2004; Jackson and Burgess, 2000; Torgersen et al., 2001; Trull et al., 2010); however, further research is needed.

To date, the prevalence of PDs among the general Australian population has been informed by the 1997 National Survey of Mental Health and Wellbeing (NSMHW). Jackson and Burgess reported that 6.5% of the Australian population (6.1% in women) screened positive for PD using the International Personality Disorder Examination (IPDE) screening questionnaire (59 items; true/false) (Jackson and Burgess, 2000). This survey also emphasised the significant disability associated with PD, underscored by frequent self-reported utilisation of health care services (Jackson and Burgess, 2002, 2004). The survey was limited by the restricted age range assessed and by the use of a screening questionnaire to identify PD, which was later described as being too brief to adequately detect cases and not validated for this purpose (Jackson and Burgess, 2000).

Good-quality epidemiological data are vital for increasing the knowledge base of the health care sector, and thus guiding public health planning and delivery of services. Of equal importance is information regarding the distribution and presentation of mental ill health across the lifespan (Newton-Howes et al., 2015). Given the paucity of current and robust epidemiological data, we aimed to report the prevalence and age distribution of PD, PD clusters and individual PDs, along with comorbid mood, anxiety, substance and eating disorders, in a representative, age-stratified sample of Australian women aged  $\geq 25$  years.

## Methods

### Participants

This study examined data collected from women enrolled in the Geelong Osteoporosis Study (GOS), an on-going, population-based cohort study originally established to describe the epidemiology of osteoporosis in Australia. The scope of the study has since expanded to examine the complex interface between a broad range of physical and mental health conditions.

Study participants were originally selected at random from the Commonwealth of Australia Electoral Commission (AEC) rolls for the Barwon Statistical Division (BSD) located in south-eastern Australia, using an age-stratified sampling method. The BSD is representative of the wider Australian population in terms of pertinent socio-demographic profiles (Pasco et al., 2012).

Originally, 1494 women participated in GOS baseline assessments (1994–1997), and an additional sample of 246 was recruited (2006–2008) aged 20–29 years using the same sampling method (Pasco et al., 2012). Further details of the study have been published elsewhere (Pasco et al., 2012; Williams et al., 2010). Of the remaining women who were eligible to participate, 849 returned for the assessment phase conducted from 2011 to 2014. Reasons for non-participation included death ( $n=392$ ), migration from the region ( $n=94$ ) or inability to be contacted ( $n=128$ ). Of the 1126 eligible participants, 277 women declined to participate citing the follow reasons: personal reasons (e.g. interference from family, invasion of privacy, not interested) ( $n=124$ ), old age/unable to cope ( $n=78$ ), time constraints ( $n=36$ ), illness ( $n=21$ ), too far to travel ( $n=5$ ), failure to keep appointment ( $n=4$ ), language barrier ( $n=1$ ) and for reasons not provided ( $n=8$ ).

Of those 849 women, 768 provided complete the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP) and Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) data and were thus included in the current analyses. Ethics approval was provided by the Barwon Health Human Research Ethics Committee, and Deakin University Human Research and Ethics Committee. All participants provided written informed consent.

### Psychiatric assessments

Psychiatric diagnoses were obtained using validated semi-structured clinical interviews (First et al., 1997, 2002). Reliability studies using a combination of joint interview and observer methods have shown the SCID-I (Zanarini et al., 2000) and SCID-II yield fair to good reliability ranges for categorical diagnoses (Maffei et al., 1997; Zanarini et al., 2000). Reliability coefficients (kappa for test–retest design) for the SCID have been shown to demonstrate fair agreement for categorical diagnoses of DSM-IV major depressive disorder (MDD) ( $\kappa=0.61$ ), poor (generalised anxiety disorder;  $\kappa=0.44$ ) through good range for anxiety disorders ( $\kappa=0.59–0.78$ ), good ranges for alcohol and other substance use disorders ( $\kappa=0.76–0.77$ ) and fair for eating disorders ( $\kappa=0.64$ ) (Zanarini et al., 2000). The presence of categorical PDs including avoidant, dependent, obsessive-compulsive, paranoid, schizotypal, schizoid, histrionic, narcissistic, borderline and antisocial was determined using the SCID-II (First et al., 1997). Reliability studies using joint interview and observer methods have shown the SCID-II yields fair–good reliability ranges for categorical diagnoses of the DSM-IV PDs: avoidant ( $\kappa=0.83–0.97$ ), dependent ( $\kappa=0.83–0.86$ ), obsessive-compulsive ( $\kappa=0.83–0.87$ ), paranoid ( $\kappa=0.93$ ), schizoid ( $\kappa=0.91$ ), schizotypal ( $\kappa=0.91$ ), histrionic ( $\kappa=0.92$ ), narcissistic ( $\kappa=0.98$ ) and borderline ( $\kappa=0.91$ ), ( $\kappa=0.78–0.98$ ) (Maffei et al., 1997; Zanarini et al., 2000).

Interviews were conducted by personnel with postgraduate qualifications in psychology, who were trained under the supervision of a psychiatrist using live and videotaped interviews as recommended by First et al. The SCID-I/NP was used to assess the presence of lifetime:

1. *Mood disorders*, that is, MDD, minor depression, dysthymia, mood disorder due to a general medical condition, substance-induced mood disorder or bipolar disorder (I, II, not otherwise specified [NOS]);
2. *Anxiety disorders*, that is, panic disorder, agoraphobia, social phobia, specific phobia, obsessive-compulsive disorder, generalised anxiety disorder (current only), anxiety disorders due to a general medical condition, substance-induced anxiety disorder and anxiety disorders NOS;
3. *Eating disorders*, that is, anorexia/bulimia nervosa, binge eating disorder;
4. *Substance use disorders*, that is, alcohol and non-alcohol substance use disorders (dependence and abuse).

The SCID-II was used to assess the lifetime presence of

5. *PDs*, that is, paranoid, schizoid, schizotypal, histrionic, narcissistic, borderline, antisocial, avoidant, dependent and obsessive-compulsive.

The Global Assessment of Functioning Scale (GAF) was used to measure aspects of functional capacities across psychological, social and occupational domains (First et al., 1997).

### Socio-demographic information

Pertinent socio-demographic information was ascertained from self-reported questionnaires and included age, country of birth, marital status and completion of secondary education. The Index of Relative Socio-economic Advantage and Disadvantage (IRSAD) was used to determine the relative socio-economic conditions of individuals and households at the area level, as previously published (Brennan et al., 2009; Williams et al., 2011). ABS software was utilised to derive the Socio-Economic Index for Areas (SEIFA) scores, providing a summary index that indicates both relative advantage and disadvantage at the small geographically-defined area level. A lower score on the IRSAD indicated relatively greater disadvantage (Quintile 1), and a higher score indicated relatively greater advantage (Quintile 5).

### Other assessments

Participants provided detailed lists and/or containers of current and prior use of medications, which were categorised

according to the classification system of MIMS pharmaceutical database). Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index (BMI, kg/m<sup>2</sup>) was derived from these measures, with obesity being defined as having a BMI > 30 kg/m<sup>2</sup>. Information regarding history of psychiatric hospitalisations was also collected during the interviews.

### Statistical analyses

'Any PD' was generated by the presence of any one or more categorical PDs; 'Cluster A' included any categorical paranoid, schizotypal or schizoid PDs; 'Cluster B' any categorical histrionic, narcissistic, borderline or antisocial PDs; 'Cluster C' any categorical avoidant, dependent or obsessive-compulsive PDs (American Psychiatric Association, 2013). Age-stratified frequencies for any PD, Clusters and individual PDs were determined for 10-year age groups (25–34, 35–44, 45–54, 55–64, 65–74, ≥75 years). Unadjusted odd ratios (ORs) with 95% confidence intervals (95% CIs) for the predictor variables of interest (age groups, socio-economic status, marital status, education, birth country, psychotropic medication use, obesity, psychiatric hospitalisation and lifetime psychiatric disorders) were calculated using logistic regression. Cross-tabulations were used to examine the frequencies (*n*) and percentage (%) of women with any PD for each predictor variable. The dependent variable was presence of 'any PD'. Differences between those with and without any PD on GAF scores were assessed using Kruskal–Wallis, with median and inter-quartile range (IQR) reported. Values of *p* < 0.05 were accepted as statistically significant. The overall prevalence estimates (with 95% CI) of any PD, Clusters and individual PDs were determined from the study population and directly standardised to the population at risk for each age group using the Australian Bureau of Statistics 2011 census data (Age by Sex; Cat. No.2001.0; Australian Bureau of Statistics, 2012; Kirkwood and Sterne, 2003). Statistical analyses were performed using Minitab Statistical Software (Version 17; Minitab, State College, PA, USA) and Stata Statistical Software (Release 13; StataCorp LP, College Station, TX, USA).

### Results

The frequencies and percentage of women with any PD according to each predictor variable of interest are presented in Table 1. The proportion of women with PD in each age group were as follows: 26.4% (25–34 years), 21.7% (35–44 years), 26.8% (45–54 years), 21.0% (55–64 years), 14.4% (65–74 years) and 13.2% (≥75 years) (Table 1). It can be seen that the youngest age group (25–34 years) was associated with increased odds of having any PD (*p* < 0.01), as was the middle age group (45–54 years) (*p* < 0.01). Other significant predictors of having any PD were psychotropic medication use (current), psychiatric

hospitalisation (ever), obesity (ever), being single/never married or separated/divorced (all *p* < 0.01). The strongest predictor of having any PD was having a lifetime history of psychiatric disorders (all *p* < 0.01). There was also a difference in GAF scores between those with any PD (70.0; IQR 60.0–80.0) compared to those without (85.0; IQR 80.0–90.0) as measured by the GAF Scale (*p* < 0.001), suggesting those with any PD had higher functional impairment.

After standardisation, the overall prevalence of any PD in Australian women was 21.8% (95% CI=[18.7, 24.9]) (Figure 1). Cluster C PDs were the most prevalent with 17.5% (95% CI=[16.0, 18.9]), followed by Cluster A with 5.3% (95% CI=[3.5, 7.0]) then Cluster B with 3.2% (95% CI=[1.8, 4.6]). Of the individual PDs, obsessive-compulsive and avoidant PDs were the most common with 10.3% (95% CI=[8.0, 12.6]) and 9.3% (95% CI=[7.1, 11.4]) meeting criteria, respectively, followed by paranoid 3.9% (95% CI=[3.1, 4.7]), borderline 2.7% (95% CI=[1.4, 4.0]), schizotypal 1.7% (95% CI=[0.7, 2.7]), schizoid 1.0% (95% CI=[0.2, 1.7]) and dependent 0.8% (95% CI=[0.16, 1.3]). We detected too few cases of narcissistic (*n*=4) and antisocial (*n*=1) PDs to calculate standardised prevalence estimates for these individual categories, and there were no cases of histrionic PD.

Frequencies of co-occurring PDs according to individual PD categories are presented in Table 2. Furthermore, of those identified with any PD (*n*=157), 73.2% (*n*=115) reported a lifetime history of psychiatric disorders. Mood disorders were the most prevalent comorbidity (63.7%; *n*=100), followed by anxiety disorders (45.2%; *n*=71). Other comorbidities reported by those with a PD included eating (11.5%; *n*=18), alcohol use (7.6%; *n*=12) and non-alcohol substance use (6.4%; *n*=10) disorders.

### Discussion

This study provides information regarding the prevalence, age distribution and comorbidity associated with PDs in a population-based sample of women. The key findings to emerge from these data were (1) approximately one in five women were estimated to have a PD, (2) PDs were most prevalent among the younger and middle-aged groups and (3) mood and anxiety disorders were the most prevalent comorbid lifetime psychiatric disorders among those with PDs as well as other co-occurring PDs. These data highlight that PDs are relatively common among the general population, and that there is a significant burden of associated psychiatric comorbidity.

Data from US population-based studies utilising semi-structured clinical interviews also suggest that the prevalence of PDs ranges between 9.0% and 21.5% (Grant et al., 2004, 2008; Pulay et al., 2009; Stinson et al., 2008; Trull et al., 2010). The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (*n*=43,093; ≥18 years) yielded a prevalence of 21.5% (pooled from two

**Table 1.** Frequencies (*n*) and percentage (%) of total sample and women with any personality disorder (PD) for each predictor variable, and logistic regression model for predicting PD presented as odds ratio (OR) with 95% confidence intervals (CIs).

Predictor variables	<i>n</i> (%) total sample	<i>n</i> (%) with PD	OR	95% CI	<i>p</i> -value
Age group, years					
25–34	106 (13.8%)	28 (26.4%)	<b>2.36</b>	<b>[1.18, 4.74]</b>	<b>0.01</b>
35–44	115 (15.0%)	25 (21.7%)	1.70	[0.90, 3.70]	0.09
45–54	127 (16.5%)	34 (26.8%)	<b>2.41</b>	<b>[1.23, 4.72]</b>	<b>0.01</b>
55–64	167 (21.7%)	35 (21.0%)	1.75	[0.91, 3.38]	0.10
65–74	139 (18.1%)	20 (14.4%)	1.11	[0.54, 2.28]	0.78
≥75 <sup>a</sup>	114 (14.8%)	15 (13.2%)	–	–	–
Socio-economic status					
Quintile 1 (most disadvantaged) <sup>a</sup>	116 (15.1%)	29 (25.0%)	–	–	–
Quintile 2	87 (11.3%)	20 (23.0%)	0.90	[0.47, 1.72]	0.74
Quintile 3	295 (38.4%)	55 (18.6%)	0.69	[0.41, 1.14]	0.15
Quintile 4	143 (18.6%)	30 (21.0%)	0.80	[0.44, 1.43]	0.44
Quintile 5	127 (16.5%)	23 (18.1%)	0.66	[0.36, 1.23]	0.19
Marital status					
Married/living with partner <sup>a</sup>	541 (70.4%)	101 (18.7%)	–	–	–
Single/never married	60 (7.8%)	18 (30.0%)	<b>1.87</b>	<b>[1.03, 3.37]</b>	<b>0.03</b>
Separated/divorced	86 (11.2%)	28 (32.6%)	<b>2.10</b>	<b>[1.28, 3.47]</b>	<b>0.004</b>
Widowed	81 (10.5%)	10 (12.3%)	0.61	[0.31, 1.23]	0.17
Birth country					
Australia and New Zealand <sup>a</sup>	667 (86.8%)	136 (20.4%)	–	–	–
United Kingdom of Great Britain and Northern Ireland	53 (6.9%)	14 (26.4%)	1.40	[0.73, 2.66]	0.30
Europe	38 (4.9%)	5 (13.2%)	0.59	[0.23, 1.54]	0.28
Other	10 (1.3%)	2 (20.0%)	0.98	[0.20, 4.65]	0.97
Education					
Did not complete secondary school	157 (20.4%)	56 (17.8%)	0.76	[0.53, 1.09]	0.13
Obesity (ever)	244 (31.8%)	64 (26.2%)	<b>1.65</b>	<b>[1.15, 2.38]</b>	<b>0.007</b>
Psychotropic medication use (current)	181 (24.1%)	54 (29.8%)	<b>1.95</b>	<b>[1.33, 2.86]</b>	<b>0.001</b>
Psychiatric hospitalisation (ever)	33 (4.3%)	15 (45.5%)	<b>3.48</b>	<b>[1.71, 7.07]</b>	<b>0.001</b>
Lifetime psychiatric disorders					
Any lifetime psychiatric disorder	353 (46.0%)	115 (32.6%)	<b>4.29</b>	<b>[2.90, 6.33]</b>	<b>&lt;0.001</b>
Lifetime mood disorder	292 (38.0%)	100 (34.2%)	<b>3.83</b>	<b>[2.65, 5.53]</b>	<b>&lt;0.001</b>
Lifetime anxiety disorder	180 (23.4%)	71 (39.4%)	<b>3.80</b>	<b>[2.61, 5.54]</b>	<b>&lt;0.001</b>
Lifetime eating disorder	35 (4.6%)	18 (51.4%)	<b>4.52</b>	<b>[2.27, 9.00]</b>	<b>&lt;0.001</b>
Lifetime alcohol use disorder	16 (2.1%)	12 (75.0%)	<b>12.56</b>	<b>[3.99, 39.50]</b>	<b>&lt;0.001</b>
Lifetime non-alcohol substance use disorder	17 (2.2%)	10 (58.8%)	<b>5.87</b>	<b>[2.20, 15.68]</b>	<b>&lt;0.001</b>

The values presented in boldface represent statistically significant values. Missing data=obesity (*n*=3); psychotropic medication use (ever) (*n*=17); row %. <sup>a</sup>Reference categories.

cross-sectional Waves) using the Alcohol Use Disorder and Associated Disability Schedule-IV (Grant et al., 2004, 2008; Pulay et al., 2009; Stinson et al., 2008), although this was substantially reduced (9.0%) when more stringent criteria for PD was utilised (Trull et al., 2010). The National Comorbidity

Survey–Replicated (NSC-R) screened population-based respondents using the IPDE screener and interviewed a probability sub-sample (*n*=214) with a semi-structured clinical interview yielding a prevalence of 9.1% for any PD (Lenzenweger et al., 2007). In a series of semi-structured

clinical interviews administered as part of the longitudinal Children in the Community study, the cumulative prevalence of PD had reached 28% in adults by mean age of 33 years (14.6% mean age 14 years, 18.1% 16 years, 22 years 25.7%) (Johnson et al., 2008). In Norway, a household survey of respondents recruited from the National Register Oslo ( $n=3,590$ ; 18–65 years) yielded a prevalence of 13.4% for any PD using the Structured Clinical Interview for DSM-III-R Personality Disorders that was administered by experienced health care providers (Torgersen et al., 2001).

Considerably lower prevalence estimates have also been reported. The household survey of United Kingdom (UK) of Great Britain (England, Wales and Scotland) reported a prevalence of 4.4% (3.4% for women only) in a sample of 628 men and women aged 16–65 years, using the same diagnostic tool as was utilised in the current study (Coid et al., 2006). Our prevalence data are also markedly higher


than previous studies utilising screening instruments (Huang et al., 2009; Jackson and Burgess, 2000), with the heterogeneity among instruments and interviewers likely to explain some of the variation in prevalence reported. The higher prevalence of less severe forms of PD such as obsessive-compulsive PD and the lower prevalence of more severe forms of PD that were detected in the current study might be another reason for the discrepancies.

### Individual PDs

Consistent with the studies from the United States, the United Kingdom and Norway, Cluster C PDs were more prevalent, than Clusters A or B PDs (Coid et al., 2006; Lenzenweger et al., 2007; Torgersen et al., 2001). Specifically, our data are concordant with prior studies that have demonstrated that obsessive-compulsive and avoidant are the most prevalent PDs among women in the general population (Grant et al., 2004; Jackson and Burgess, 2000; Torgersen et al., 2001; Trull et al., 2010). In fact, the overall prevalence of PDs in the current study was largely attributable to cases of obsessive-compulsive PD (10.3%). Clinically-based data also indicate that obsessive-compulsive, avoidant and borderline PDs are among the most common PDs in psychiatric patients receiving treatment (Zimmerman et al., 2005).

Prior studies have reported that the prevalence of obsessive-compulsive PD among women ranges between 1.3% and 7.9% (Coid et al., 2006; Grant et al., 2004; Jackson and Burgess, 2000). Given the nature of obsessive-compulsive PD, continued participation in research studies such as the GOS, might be expected and might account for the overrepresentation of this PD in the current study. Furthermore, obsessive-compulsive PD features have been shown to be more stable over time compared with other PDs and mental state disorders such as MDD (Grilo et al., 2004). Inconsistent

**Figure 1.** Prevalence of personality disorders standardised to Australian population (2011) (error bars represent 95% CI).



'Any' includes individual PDs: paranoid, schizoid, schizotypal, narcissistic, borderline, antisocial, avoidant, dependent and obsessive-compulsive.

**Table 2.** Frequency of co-occurring personality disorders (PDs) according to individual PD categories.

	1 PD	2 PDs	3 PDs	≥4 PDs
Paranoid	11 (45.8%)	5 (20.8%)	2 (8.3%)	6 (25.0%)
Schizoid	3 (42.86%)	2 (28.6%)	1 (14.3%)	1 (14.3%)
Schizotypal	3 (27.3%)	2 (18.2%)	2 (18.2%)	4 (36.4%)
Narcissistic	1 (25.0%)	1 (25.0%)	–	2 (50.0%)
Borderline	5 (29.4%)	6 (35.3%)	2 (11.8%)	4 (23.5%)
Antisocial	–	–	1 (100%)	–
Avoidant	47 (67.1%)	16 (22.9%)	3 (4.3%)	4 (5.7%)
Dependent	4 (57.1%)	–	1 (14.3%)	2 (28.6%)
Obsessive-compulsive	46 (63.9%)	18 (25.0%)	3 (4.2%)	5 (6.9%)

Row %.

associations between obsessive-compulsive PD and disability have been previously reported (Grant et al., 2004), suggesting that both higher and lower functioning individuals with this disorder can meet threshold criteria. Clinically-based data also indicate that while patients with obsessive-compulsive PD show little improvement over time on measures of psychosocial functioning, these patients suffered less impairment compared with other PDs (Skodol et al., 2005).

In contrast, borderline PD is considered a severe form of PD, which was found to be similar (2.7%) to what has been previously reported. A prior examination of PD in an Australian population-based study of younger adults ( $n=1520$ ; mean age 24.1 years) indicated the prevalence of borderline PD (assessed using the International Classification of Diseases [ICD-10] version of the Standardised Assessment Personality) was 3.5% ( $n=1145$ ; any PD 18.6%), with more young women being identified than young men (Moran et al., 2006).

Avoidant PD was more prevalent in our study than the previously reported range of 0.7–2.76% (Coid et al., 2006; Grant et al., 2004; Jackson and Burgess, 2000). One possible explanation might be associated with the central feature of this disorder being ‘*a desire to be accepted, despite hypersensitivities to rejection*’ (American Psychiatric Association, 2013). Most of the participants enrolled in the GOS have participated in numerous follow-up appointments, thereby potentially reducing perceived potential dangers or threats. Furthermore, given the high comorbidity and criterion overlap between avoidant PD and anxiety disorders, in particular social phobia, it is possible that some cases of avoidant PD might have been better accounted for by social phobia. On the whole, it remains likely that Cluster C PD features such as a desire to please and perfectionism might drive higher rates of retention in a long-term cohort study. On the other hand, high impulsivity and related Cluster B features might result in low retention in this study, providing a falsely low prevalence. For example, in the current study, fewer individuals with avoidant or obsessive-compulsive PDs had more than one co-occurring PD, indicating that PD comorbidity might be a driver of severity (Tyrer and Johnson, 1996), thus potentially influencing participation. It is also likely that the low prevalence of antisocial PD in the current study is due to sex differences, with other studies reporting the prevalence of antisocial PD being higher among men (Lenzenweger et al., 2006).

Cluster A PDs were the next most prevalent as a group, with paranoid PD being the most common in this Cluster (5.3%). This pattern was similarly reported in the NSC-R (Lenzenweger et al., 2007), Great Britain Household Survey (Coid et al., 2006) and the NESARC (Grant et al., 2004); however, our study reported higher prevalence for each PD Cluster. Still, consistent with these prior studies, the prevalence of the remaining individual PDs in the current study was low (all  $\leq 1.7\%$ ). While Cluster A PDs have been shown to be more prevalent than Cluster B PDs, the latter have

received greater attention, and Cluster A PDs remain relatively under-studied in general population settings.

### Age distribution

In the present study, a higher proportion of PDs were observed among the younger age group as well as the middle-aged group. Prior studies have also reported that those with PD tend to be younger (Coid et al., 2006; Jackson and Burgess, 2000; Torgersen et al., 2001). Until recently, there have been few studies examining the prevalence of PD across the full adult lifespan. Data from the NESARC reported age-stratified prevalence for PDs among adults aged 55 years and over (women: 16.1% 55–64 years; 11.6% 65–74 years; 9.4% 75–84 years, 8.7% 85+ years) (Reynolds et al., 2015).

The features characteristic of Cluster B PDs, such as symptoms and behaviours associated with impulsivity and affective instability, have been shown to be particularly characteristic among younger adults (Zanarini et al., 2008) and are susceptible to a fluctuating course (Gunderson et al., 2011; Zanarini et al., 2008, 2012), suggesting ‘burn out’ of these behavioural features over time. A number of studies have further highlighted the clinical differences between the presentation of symptoms among younger adults who present with borderline PD including impulsivity, affective instability and increased severity of symptoms being associated with younger age (Yang et al., 2010; Zanarini et al., 2008); in contrast, older adults appear more likely to experience chronic emptiness, and reduced features of impulsivity and affective instability (Morgan et al., 2013). Other clinically-based studies indicate that Cluster C PD features are more enduring (Durbin and Klein, 2006; Ferro et al., 1998; Grilo et al., 2004).

A higher proportion of women aged 45–54 years were also more likely to have any PD in the current study. Developmentally, there are many domains that might be related to personality pathology among women in this age group, including physical health, social relationships and major life experiences (Oltmanns and Balsis, 2011). Finally, increasing age is a known risk factor for poorer physical functioning and physical morbidity. Physical health problems and psychiatric comorbidity are also commonly reported among older adults (El-Gabalawy et al., 2011). It is possible that the higher prevalence of PD observed in the current sample, might be associated with poorer physical health status. Currently, one can only speculate upon the developmental trajectory of PD across lifespan from the current cross-sectional data, with longitudinal analyses needed to investigate age-related patterns as they emerge from adolescence through to middle and older adulthood.

### Lifetime comorbidities

Among those with any PD, the lifetime comorbidity with any mental state disorder in the present study was 73.3%,

concordant with prior Australian data reporting 40.9–77.8% (Jackson and Burgess, 2002). We identified mood (63.7%) and anxiety disorders (45.2%) as the most common comorbidity disorders, being consistent with previous clinically-based (Zimmerman et al., 2005) and population-based data (Jackson and Burgess, 2000). We also reported comorbid alcohol and other non-alcohol substance use disorders (7.7% and 6.4%, respectively). According to the clinically-based US Collaborative Longitudinal Personality Disorders Study, up to 85% of those with PDs are reported to suffer from mood disorders, particularly recurrent MDD (Gunderson et al., 2008). Conversely, the clinically-based ( $n=391$  outpatients) Rhode Island Methods to Improve Diagnostic Assessment and Services study (Zimmerman et al., 2005) reported that 31.4% of the patients with mood disorders and other psychiatric conditions had at least one PD.

In the current study, those with PD also reported a markedly higher proportion of comorbid lifetime eating disorders compared with those without PD (11.5% vs 2.8%). In comparison with other psychiatric disorders, the investigation of comorbid eating disorders has received less attention. Interestingly, a study examining consecutive patients receiving treatment for eating disorders ( $n=545$ , ages 18–54 years) found that certain PD features were more common among specific sub-types of eating disorders than others (Godt, 2008). Godt (2008) found that Cluster B PDs were more common (15.1%) among those with bulimia nervosa–purging type, Cluster C PDs more common (28.6%) among those with bulimia nervosa–non-purging-type, whereas the prevalence of Cluster A PDs was relatively low ( $\leq 2.3\%$ ) across all sub-types of eating disorders.

### Socio-demographic correlates

Consistent with several population-based studies (Coid et al., 2006; Huang et al., 2009; Jackson and Burgess, 2000; Torgersen et al., 2001), being single/never married or separated/divorced was predictive of having any PD. They also tended to be more socially disadvantaged (not significant). Others have reported that those with PD are particularly likely to be living in urban areas (Coid et al., 2006; Torgersen et al., 2001), face unemployment and have lower levels of educational attainment (Coid et al., 2006; Jackson and Burgess, 2000; Torgersen et al., 2001).

### Strengths and limitations

A major strength of the current study is the comprehensive psychiatric assessments that were used to identify PDs and psychiatric comorbidities. Additionally, we investigated a random, age-stratified, population-based sample, spanning the full adult age range. We also utilised a robust measure of relative advantage and disadvantage (IRSAD) that extends prior studies that have relied on self-reported information alone to measure socio-economic status. However,

it is possible that a response bias may exist, given the higher proportion of PDs observed in quintiles 1 and 2. As such, the current study provides a valuable contribution to the literature given the paucity of good quality epidemiological data derived from the general Australian population.

There are also potentially important limitations to consider when interpreting our data. First, the psychiatric profile of GOS non-respondents may have differed from responders. Also, we cannot exclude the possibility of differential loss to follow-up, in relation to PDs, over the course of the study. The reduced sample for which complete psychiatric data were available may have further introduced bias. Our sample might also differ from the underlying population in terms of patterns of migration and cultural diversity. Given that there is a paucity of prior data collected utilising the same assessment tool, comparisons of our data with other populations in Australia should be made with caution. Furthermore, we cannot rule out that both recall and information bias were introduced when administering the semi-structured clinical interviews, despite strict adherence to protocols. Moreover, precision of the overall prevalence estimates, particularly among less frequent PDs as well as predictor variables with smaller frequencies, must be interpreted with caution. The current study only provided prevalence estimates for categorical diagnoses (i.e. the assessment of specific personality types); it is acknowledged that this does not provide a complete picture regarding the dimensions or levels of PD severity in our study (Tyrer and Johnson, 1996). Therefore, caution should be exercised when interpreting our findings and anticipating the future health care needs of individuals with PD with varying levels of symptom severity. While we provided a comprehensive assessment of psychiatric disorders, psychotic and cognitive disorders were not assessed. Finally, these data are cross-sectional, thereby precluding examination of the longitudinal trajectory of PD.

### Future directions and conclusions

First, complementary data are needed regarding the prevalence of PD among Australian men. Second, further investigations are warranted regarding associations between PDs with mental state disorders, particularly eating disorders, where there are few data. There also remains a need for more in-depth investigations into the socio-economic profile of PD among both women and men, in order to further identify sub-groups of the population who might be at risk of PD, and also to understand the needs of those with PD living with social disadvantage. Finally, we suggest that further investigations are required regarding the associated disability among those with PD in the general Australian population, as well as psychiatric and physical comorbidities and associated help-seeking behaviours, in order to address needs for therapeutic intervention (Quirk et al., 2015), which will be explored in separate analyses. In conclusion, these data emphasise that PDs are relatively common among the

Australian population, and provide much needed epidemiological data that might inform and guide public health planning and delivery of services.

### Acknowledgements

The authors' acknowledge the research personnel and participants of the Geelong Osteoporosis Study.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Geelong Osteoporosis Study is funded by the National Health and Medical Research Council (NHMRC of Australia, projects 454356 and 628582) and the Victorian Health Promotion Foundation. S.E.Q. was supported by a NHMRC Public Health and Health Services Research Postgraduate Scholarship (GNT1076347) and is currently supported by a Deakin University Health Research Postdoctoral Fellowship. M.B. has received Grant/Research Support from the National Institute of Health (USA), Simons Foundation, CRC for Mental Health, Stanley Medical Research Institute, Medical Benefits Fund, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer; a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth; and is supported by a NHMRC Senior Principal Research Fellowship (GNT1059660). J.A.P. has received grants from the NHMRC, BUPA Foundation, Deakin University, Barwon Health and the Western Alliance Academic Health Science Centre. S.L.B.-O. has received Grant/Research support from The University of Melbourne, Deakin University, an Alfred Deakin Postdoctoral Research Fellowship, has received speaker fees from Amgen (2015) and is currently supported by a NHMRC Career Development Fellowship (GNT1107510). A.M.C. has received research funding from the NHMRC, Australian Research Council (ARC), Colonial Foundation, The University of Melbourne, Melbourne Health and the New South Wales Department of Health. H.J.J. has received funding from NHMRC, ARC, University of Melbourne, Beyond Blue and Australian Rotary Health. C.A.O. was supported by an ARC Senior Research Fellowship (DORA: DP130101459). L.J.W. has received Grant/Research support from Eli Lilly, Pfizer, The University of Melbourne, Deakin University and the NHMRC, and is supported by a NHMRC Career Development Fellowship (GNT1064272).

### References

- American Psychiatric Association (2013) *Diagnostic and Statistical Manual of Mental Disorders*, 5th Edition. Arlington, VA: American Psychiatric Publishing.
- Ansell EB, Wright AG, Markowitz JC, et al. (2015) Personality disorder risk factors for suicide attempts over 10 years of follow-up. *Personality Disorders* 6: 161–167.

- Australian Bureau of Statistics (2012) *Census of population and housing: Basic community profile 2011 third release*. Age by Sex, Cat. no. 2001.0. Available at: [www.abs.gov.au/ausstats/abs@.nsf/mf/2001.0](http://www.abs.gov.au/ausstats/abs@.nsf/mf/2001.0)
- Brennan SL, Henry MJ, Wluka AE, et al. (2009) BMD in population-based adult women is associated with socioeconomic status. *Journal of Bone and Mineral Research* 24: 809–815.
- Coid J, Yang M, Bebbington P, et al. (2009) Borderline personality disorder: Health service use and social functioning among a national household population. *Psychological Medicine* 39: 1721–1731.
- Coid J, Yang M, Tyrer P, et al. (2006) Prevalence and correlates of personality disorder in Great Britain. *British Journal of Psychiatry* 188: 423–431.
- Durbin CE and Klein DN (2006) Ten-year stability of personality disorders among outpatients with mood disorders. *Journal of Abnormal Psychology* 115: 75–84.
- El-Gabalawy R, Mackenzie CS, Shooshtari S, et al. (2011) Comorbid physical health conditions and anxiety disorders: A population-based exploration of prevalence and health outcomes among older adults. *General Hospital Psychiatry* 33: 556–564.
- Ferro T, Klein DN, Schwartz JE, et al. (1998) 30-month stability of personality disorder diagnoses in depressed outpatients. *American Journal of Psychiatry* 155: 653–659.
- First M, Gibbon M, Spitzer R, et al. (1997) *Structured Clinical Interview for DSM-IV Axis I Personality Disorders, (SCID-II)*. Washington, DC: American Psychiatric Press, Inc.
- First M, Spitzer R, Gibbon M, et al. (2002) *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP)*. New York: New York State Psychiatric Institute, Biometrics Research.
- Fok ML, Hayes RD, Chang CK, et al. (2012) Life expectancy at birth and all-cause mortality among people with personality disorder. *Journal of Psychosomatic Research* 73: 104–107.
- Godt K (2008) Personality disorders in 545 patients with eating disorders. *European Eating Disorders Review* 16: 94–99.
- Grant BF, Chou SP, Goldstein RB, et al. (2008) Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: Results from the Wave 2 National epidemiologic survey on alcohol and related conditions. *Journal of Clinical Psychiatry* 69: 533–545.
- Grant BF, Hasin DS, Stinson FS, et al. (2004) Prevalence, correlates, and disability of personality disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Clinical Psychiatry* 65: 948–958.
- Grilo CM, Sanislow CA, Gunderson JG, et al. (2004) Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. *Journal of Consulting and Clinical Psychology* 72: 767–775.
- Gunderson JG, Stout RL, McGlashan TH, et al. (2011) Ten-year course of borderline personality disorder: Psychopathology and function from the collaborative longitudinal personality disorders study. *Archives of General Psychiatry* 68: 827–837.
- Gunderson JG, Stout RL, Sanislow CA, et al. (2008) New episodes and new onsets of major depression in borderline and other personality disorders. *Journal of Affective Disorders* 111: 40–45.
- Huang Y, Kotov R, de Girolamo G, et al. (2009) DSM-IV personality disorders in the WHO World Mental Health Surveys. *British Journal of Psychiatry* 195: 46–53.
- Jackson HJ and Burgess PM (2000) Personality disorders in the community: A report from the Australian National Survey of mental health and wellbeing. *Social Psychiatry and Psychiatric Epidemiology* 35: 531–538.
- Jackson HJ and Burgess PM (2002) Personality disorders in the community: Results from the Australian National Survey of mental health and wellbeing part II: Relationships between personality disorder, Axis I mental disorders and physical conditions with disability and health consultations. *Social Psychiatry and Psychiatric Epidemiology* 37: 251–260.

- Jackson HJ and Burgess PM (2004) Personality disorders in the community: Results from the Australian National Survey of mental health and wellbeing part III: Relationships between specific type of personality disorder, Axis I mental disorders and physical conditions with disability and health consultations. *Social Psychiatry and Psychiatric Epidemiology* 39: 765–776.
- Johnson JG, Cohen P, Kasen S, et al. (2008) Cumulative prevalence of personality disorders between adolescence and adulthood. *Acta Psychiatrica Scandinavica* 118: 410–413.
- Kirkwood BR and Sterne JAC (2003) *Essential Medical Statistics*, 2nd edn. Malden, MA: Blackwell Publishing.
- Lenzenweger MF, Lane MC, Loranger AW, et al. (2007) DSM-IV personality disorders in the National comorbidity survey replication. *Biological Psychiatry* 62: 553–564.
- Maffei C, Fossati A, Agostoni I, et al. (1997) Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. *Journal of Personality Disorders* 11: 279–284.
- Moran P, Coffey C, Mann A, et al. (2006) Personality and substance use disorders in young adults. *British Journal of Psychiatry* 188: 374–379.
- Morgan TA, Chelminski I, Young D, et al. (2013) Differences between older and younger adults with borderline personality disorder on clinical presentation and impairment. *Journal of Psychiatric Research* 47: 1507–1513.
- Newton-Howes G, Clark L and Chanen A (2015) Personality disorder across the life course. *The Lancet* 385: 727–734.
- Oltmanns TF and Balsis S (2011) Personality disorders in later life: Questions about the measurement, course, and impact of disorders. *Annual Review of Clinical Psychology* 7: 321–349.
- Pasco JA, Nicholson GC and Kotowicz MA (2012) Cohort profile: Geelong Osteoporosis Study. *International Journal of Epidemiology* 41: 1565–1575.
- Pulay AJ, Stinson FS, Dawson DA, et al. (2009) Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: Results from the wave 2 national epidemiologic survey on alcohol and related conditions. *Primary Care Companion Journal of Clinical Psychiatry* 11: 53–67.
- Quirk SE, Williams LJ, Chanen AM and Berk M (2015) Contribution of personality disorder to population mental health and disease burden. *The Lancet Psychiatry* 2: 201–202.
- Reynolds K, Pietrzak RH, El-Gabalawy R, et al. (2015) Prevalence of psychiatric disorders in U.S. older adults: Findings from a nationally representative survey. *World Psychiatry* 14: 74–81.
- Sareen J, Afifi TO, McMillan KA, et al. (2011) Relationship between household income and mental disorders: Findings from a population-based longitudinal study. *Archives of General Psychiatry* 68: 419–427.
- Skodol AE, Pagano ME, Bender DS, et al. (2005) Stability of functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder over two years. *Psychological Medicine* 35: 443–451.
- Stinson FS, Dawson DA, Goldstein RB, et al. (2008) Prevalence, correlates, disability, and comorbidity of DSM-IV narcissistic personality disorder: Results from the wave 2 national epidemiologic survey on alcohol and related conditions. *Journal of Clinical Psychiatry* 69: 1033–1045.
- Torgersen S, Kringlen E and Cramer V (2001) The prevalence of personality disorders in a community sample. *Archives of General Psychiatry* 58: 590–596.
- Trull TJ, Jahng S, Tomko RL, et al. (2010) Revised NESARC personality disorder diagnoses: Gender, prevalence, and comorbidity with substance dependence disorders. *Journal of Personality Disorders* 24: 412–426.
- Tyrer P and Johnson T (1996) Establishing the severity of personality disorder. *American Journal of Psychiatry* 153: 1593.
- Williams L, Jacka F, Pasco J, et al. (2010) The prevalence of mood and anxiety disorders in Australian women. *Australasian Psychiatry* 18: 250–255.
- Williams LJ, Brennan SL, Henry MJ, et al. (2011) Area-based socioeconomic status and mood disorders: Cross-sectional evidence from a cohort of randomly selected adult women. *Maturitas* 69: 173–178.
- Yang M, Coid J and Tyrer P (2010) Personality pathology recorded by severity: National survey. *British Journal of Psychiatry* 197: 193–199.
- Zanarini MC, Frankenburg FR, Reich DB, et al. (2008) The 10-year course of physically self-destructive acts reported by borderline patients and axis II comparison subjects. *Acta Psychiatrica Scandinavica* 117: 177–184.
- Zanarini MC, Frankenburg FR, Reich DB, et al. (2012) Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: A 16-year prospective follow-up study. *American Journal of Psychiatry* 169: 476–483.
- Zanarini MC, Skodol AE, Bender D, et al. (2000) The collaborative longitudinal personality disorders study: Reliability of axis I and II diagnoses. *Journal of Personality Disorders* 14: 291–299.
- Zimmerman M, Rothschild L and Chelminski I (2005) The prevalence of DSM-IV personality disorders in psychiatric outpatients. *American Journal of Psychiatry* 162: 1911–1918.